While both groups showed reduction of tumor volume compared to the tumors without gemcitabine, VCAM-1-overexpressing tumors showed significantly less reduction of tumor volume compared to that of control tumors (30% vs 51% reduction, respectively) after gemcitabine treatment (Fig. 2C). The gene discussed is VCAM1; the disease is neoplasm.